Figure 3
PFS and OS according to MRD/therapy groups. (A) Patients achieving MRD-negative status after 3 or more courses of FCR, irrespective of MRD status at intermediate staging, had similar PFS (P = NS). Patients with MRD-negative status had a longer PFS than patients with MRD-positive status receiving 3 (P < .001) or more (P = .05) courses of FCR. (B) Patients achieving MRD-negative status after 3 or more courses of FCR, irrespective of MRD status at intermediate staging, or MRD-positive patients receiving more than 3 courses of FCR, had similar OS (P = NS). Patients with MRD-negative status or MRD-positive status but receiving more than 3 courses of FCR had a longer OS than patients with MRD-positive status receiving only 3 courses of FCR (P < .001). NS, not significant.

PFS and OS according to MRD/therapy groups. (A) Patients achieving MRD-negative status after 3 or more courses of FCR, irrespective of MRD status at intermediate staging, had similar PFS (P = NS). Patients with MRD-negative status had a longer PFS than patients with MRD-positive status receiving 3 (P < .001) or more (P = .05) courses of FCR. (B) Patients achieving MRD-negative status after 3 or more courses of FCR, irrespective of MRD status at intermediate staging, or MRD-positive patients receiving more than 3 courses of FCR, had similar OS (P = NS). Patients with MRD-negative status or MRD-positive status but receiving more than 3 courses of FCR had a longer OS than patients with MRD-positive status receiving only 3 courses of FCR (P < .001). NS, not significant.

Close Modal

or Create an Account

Close Modal
Close Modal